Horizon Therapeutics gains amid speculation on potential FTC settlement on Amgen
JHVEPhoto/iStock Editorial via Getty Images
Horizon Therapeutics (NASDAQ:HZNP) rose 1.1%, at least partly amid some speculation about a potential settlement with the Federal Trade Commission over it lawsuit to block the planned $28 billion sale to Amgen (NASDAQ:AMGN).
"There continues to be a belief that the two sides, or I should say the FTC and Amgen, will somehow cobble together some sort, something they will call a settlement, that allows Amgen to go on and allows the FTC to at least not actually have to lose in court as so many people think they will," CNBC's David Faber said earlier on Monday. 
Faber's latest comments come as Amgen (AMGN) and the FTC last month said there are no ongoing talks to try to come to a settlement over the antitrust regulators block on the Horizon deal. Both Amgen and the FTC said that there have been discussions in the past. In June, Faber reported that the companies had talks with the FTC, though they didn't lead to a settlement.
Amgen CEO Robert Bradway said earlier this month that the FTC has ignored the commitments that the company has made to address the regulator's concerns around the deal. Bradway said the company is working on integration plans with Horizon (HZNP) so the companies can combine by mid-December, when he expects the deal to close.
"Simply put, there are no competitive overlaps and no incentives to bundle our drugs with theirs," Bradway said on the company's Q2 earnings call.
Amgen (AMGN) said in June it would not close the deal before Oct. 31 or the second business day after the court rules on the FTC's request to block the deal. U.S. District Judge John Kness set a hearing for September on the FTC's efforts to block the combination.

More on Horizon Therapeutics

Horizon Therapeutics: Can Investors Profit From Amgen Deal Confusion?
Improved Outlook For Horizon Therapeutics And Amgen
Horizon Therapeutics, Activision among best bets for M&A deals to close

2023 shaping up to be biggest year for biopharma M&A since pandemic
Amgen says FTC has ignored commitments it made to address Horizon deal concerns (update)
Seeking Alphaâs Quant Rating on Horizon Therapeutics
Earnings data for Horizon Therapeutics
Dividend for Horizon Therapeutics